New Global Fund head targets killer diseases with cash

The Global Fund's new executive director, Mark Dybul, said he will move quickly to raise fresh money and release funding to combat the killer diseases AIDS, malaria and tuberculosis.
New scientific research shows that these diseases can be contained and his mission will be to achieve that in partnership with hard-hit countries, Dybul said in an interview on Thursday shortly after his appointment to head the epidemic-fighting agency based in Geneva.
"We are going to move aggressively to get money out of the door," said Dybul, a former US global AIDS co-ordinator. "We will be working to increase the resources of the Fund and its contributions. We will be very aggressive."
"We have the scientific knowledge to completely control these diseases, and we want to have the resources," Dybul added, although he did not set time frames nor financial goals.
Since its founding in 2002, the Global Fund to Fight AIDS, Tuberculosis and Malaria has approved $22.9 billion in funding for more than 1,000 programs in 151 countries. Its programs have helped treat 3.6 million people with AIDS, 9.3 million with anti-TB treatments and delivered 270 million insecticide-treated mosquito nets to prevent malaria, it said.
Dybul joins the Global Fund after a turbulent year for the public-private organisation.
Set up a decade ago to combat the three epidemics, it was forced to halt new program funding in face of a revenue shortfall after the start of the global financial crisis. The Global Fund also faced criticism over misuse of funds, prompting its head, Michel Kazatchkine of France, to step down in January.
Its chief auditor, John Parson, was fired on Thursday after the board deemed his performance "unsatisfactory."
Dybul, an AIDS clinician with a specialty in immunology who held leading posts under former US President George W. Bush at the President's Emergency Program for AIDS Relief and as an ambassador for AIDS, brushed aside any concern about the recent upheavals at the Fund. "It is on a very strong forward trajectory," he said. "It is in a very strong position and has a very strong emphasis on value for money and focus on the three killer diseases."
The Fund's board also on Thursday approved a new funding model, starting in 2013, that is designed to be simpler, more flexible and have greater impact in conquering the diseases.